Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jan 5;18(1):51–62. doi: 10.1080/15384047.2016.1276126

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Author(s). Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

PMC Copyright notice

Figure 1. — The antitumor efficacy of metuzumab combined with GP, TP or NP in vitro and in vivo. (A) Tumor growth inhibition with metuzumab alone or combined with GP, TP or NP in Balb/c nude mice bearing A549 (left), NCI-H460 (middle) and NCI-H520 (right) human lung cancer cell line xenografts. Data are presented as tumor volume (mm³) in the means ± SD (n = 10). (B) Analysis of cell-growth rate by modified MTT assay. (C) Representative images of metuzumab distribution in nude mice bearing A549, NCI-H460 and NCI-H520 cell xenograft. Each experiment was repeated for at least 3 times.